Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             38 results found
no title author magazine year volume issue page(s) type
1 Androgen receptor as a target in androgen-independent prostate cancer Balk, Steven P
 2002
 60 3S1 p. 132-138
7 p.
 article
2 Antiandrogen monotherapy: indications and results Iversen, Peter
 2002
 60 3S1 p. 64-71
8 p.
 article
3 A review of measurement of patient preferences for treatment outcomes after prostate cancer Lubeck, Deborah P
 2002
 60 3S1 p. 72-77
6 p.
 article
4 Chemotherapy for prostate cancer Gilligan, Timothy
 2002
 60 3S1 p. 94-100
7 p.
 article
5 CME assessment test and evaluation form 2002
 60 3S1 p. 141-145
5 p.
 article
6 Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer Meng, Maxwell V
 2002
 60 3S1 p. 7-11
5 p.
 article
7 Discussion following Dr. Balk’s presentation 2002
 60 3S1 p. 138-139
2 p.
 article
8 Discussion following Dr. Carroll’s presentation 2002
 60 3S1 p. 11-12
2 p.
 article
9 Discussion following Dr. D’Amico’s presentation 2002
 60 3S1 p. 37-38
2 p.
 article
10 Discussion following Dr. George’s presentation 2002
 60 3S1 p. 122-
1 p.
 article
11 Discussion following Dr. Grossfeld’s presentation 2002
 60 3S1 p. 62-63
2 p.
 article
12 Discussion following Dr. Johnson’s presentation 2002
 60 3S1 p. 130-131
2 p.
 article
13 Discussion following Dr. Kantoff’s presentation 2002
 60 3S1 p. 100-
1 p.
 article
14 Discussion following Dr. Kelly’s presentation 2002
 60 3S1 p. 113-114
2 p.
 article
15 Discussion following Dr. Klotz’s presentation 2002
 60 3S1 p. 51-
1 p.
 article
16 Discussion following Dr. Klotz’s presentation 2002
 60 3S1 p. 56-
1 p.
 article
17 Discussion following Dr. Lee’s presentation 2002
 60 3S1 p. 44-
1 p.
 article
18 Discussion following Dr. Lubeck’s presentation 2002
 60 3S1 p. 77-78
2 p.
 article
19 Discussion following Dr. Mcleod’s presentation 2002
 60 3S1 p. 21-
1 p.
 article
20 Discussion following Dr. Oh’s presentation 2002
 60 3S1 p. 93-
1 p.
 article
21 Discussion following Dr. Pollack’s presentation 2002
 60 3S1 p. 30-31
2 p.
 article
22 Discussion following Dr. Sartor’s presentation 2002
 60 3S1 p. 107-108
2 p.
 article
23 Discussion following Dr. Smith’s presentation 2002
 60 3S1 p. 86-
1 p.
 article
24 Emerging role of adjuvant hormonal therapy Mcleod, David G
 2002
 60 3S1 p. 13-20
8 p.
 article
25 Endpoints in prostate cancer clinical trials Sartor, Oliver
 2002
 60 3S1 p. 101-107
7 p.
 article
26 Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer Pollack, Alan
 2002
 60 3S1 p. 22-30
9 p.
 article
27 Intermittent androgen suppression in prostate cancer: the Canadian experience Hurtado-Coll, Antonio
 2002
 60 3S1 p. 52-56
5 p.
 article
28 Newer approaches to androgen deprivation therapy in prostate cancer 2002
 60 3S1 p. iv-v
nvt p.
 article
29 Novel trial designs: which agents and how do we test them? Kelly, William Kevin
 2002
 60 3S1 p. 109-113
5 p.
 article
30 Osteoporosis during androgen deprivation therapy for prostate cancer Smith, Matthew R
 2002
 60 3S1 p. 79-85
7 p.
 article
31 Overview consensus statement 1 1 This supplement and conference were funded by an unrestricted educational grant from AstraZeneca Pharmaceuticals. Myles A. Brown is a paid consultant to, and is a study investigator funded by, Novartis Pharmaceuticals. Daniel J. George is a paid consultant to and a member of the speakers’ bureau for Novartis Pharmaceuticals; a paid consultant to TAP Pharmaceuticals; holds stock in and is on the editorial staff for Veritas Medicine; and is a study investigator funded by Wyeth-Ayerst. William Kevin Kelly is a member of the medical advisory board for Amgen Pharmaceuticals and a member of the speakers’ bureau for AstraZeneca Pharmaceuticals and Bristol-Meyers Squibb. Laurence Klotz is a member of the speakers’ bureau for and a paid consultant to AstraZeneca Pharmaceuticals; a paid consultant to Aventis Pharmaceuticals; and a study investigator funded by Abbott Laboratories Canada. W. Robert Lee is a member of the medical advisory board for Nycomed-Amersham. Deborah P. Lubeck is a study investigator funded by TAP Pharmaceuticals. David G. McLeod is a study investigator funded by AstraZeneca Pharmaceuticals. Alan Pollack is a paid consultant to Amgen Pharmaceuticals, AstraZeneca Pharmaceuticals, and TAP Pharmaceuticals. Oliver Sartor is a paid consultant to and a member of the medical advisory board for Atrix Pharmaceuticals. Matthew R. Smith is a study investigator funded by AstraZeneca Pharmaceuticals and is a paid consultant to and a study investigator funded by Novartis Pharmaceuticals. Carroll, Peter R
 2002
 60 3S1 p. 1-6
6 p.
 article
32 Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy Grossfeld, Gary D
 2002
 60 3S1 p. 57-62
6 p.
 article
33 Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the canadian experience Hurtado-coll, Antonio
 2002
 60 3S1 p. 45-51
7 p.
 article
34 Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer D’Amico, Anthony V.
 2002
 60 3S1 p. 32-37
6 p.
 article
35 Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate George, Daniel J
 2002
 60 3S1 p. 115-121
7 p.
 article
36 Secondary hormonal therapies in the treatment of prostate cancer OH, William K
 2002
 60 3S1 p. 87-92
6 p.
 article
37 The role of androgen deprivation therapy combined with prostate brachytherapy Lee, W.Robert
 2002
 60 3S1 p. 39-44
6 p.
 article
38 Vitamin d receptor: a potential target for intervention Johnson, Candace S
 2002
 60 3S1 p. 123-130
8 p.
 article
                             38 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands